Silver Spring, Maryland–(ENEWSPF)–April 7, 2011. On April 6, the U.S. Food and Drug Administration approved Horizant Extended Release Tablets (gabapentin enacarbil), a once-daily treatment for moderate-to-severe restless legs syndrome (RLS).
FDA Approves Horizant to Treat Restless Legs Syndrome
More in Health and Fitness:
